ReShape Lifesciences Inc HIND Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.58 down $0.05, 3.07% at close Nov 6
Last close · Previous close $1.63
- Market cap
- $11.09MAt the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$1.58down $0.48, 23.30%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.63Nov 5
- Volume19.78KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume12.54KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.57 to $5.88; now $1.58
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
HIND trailed the S&P 500 in all 7 periods.
| Period | HIND and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | HIND: down 23.3% S&P 500: down 5.6% | HIND trailed the S&P 500 by 17.7 percentage points Trailed |
| 3M | HIND: down 26.2% S&P 500: down 4.1% | HIND trailed the S&P 500 by 22.1 percentage points Trailed |
| YTD | HIND: down 54.1% S&P 500: up 8.7% | HIND trailed the S&P 500 by 62.8 percentage points Trailed |
| 1Y | HIND: down 72.1% S&P 500: up 10.9% | HIND trailed the S&P 500 by 83.0 percentage points Trailed |
| Long term | ||
| 3Y | HIND: down 99.9% S&P 500: up 75.0% −89.5% vs +20.5% a year | HIND trailed the S&P 500 by 174.9 percentage points Trailed |
| 5Y | HIND: down 100.0% S&P 500: up 67.8% −92.7% vs +10.9% a year | HIND trailed the S&P 500 by 167.8 percentage points Trailed |
| 10Y | HIND: down 100.0% S&P 500: up 313.1% −81.0% vs +15.2% a year | HIND trailed the S&P 500 by 413.1 percentage points Trailed |
$10,000 invested in HIND 10 years ago (Nov 4, 2016) would be worth about $0 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
HIND trailed the S&P 500 in all 7 periods.
| Period | HIND and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | HIND: down 23.3% S&P 500: down 5.6% | HIND trailed the S&P 500 by 17.7 percentage points Trailed |
| 3M | HIND: down 26.2% S&P 500: down 4.3% | HIND trailed the S&P 500 by 21.9 percentage points Trailed |
| YTD | HIND: down 54.1% S&P 500: up 7.8% | HIND trailed the S&P 500 by 61.9 percentage points Trailed |
| 1Y | HIND: down 72.1% S&P 500: up 9.7% | HIND trailed the S&P 500 by 81.8 percentage points Trailed |
| Long term | ||
| 3Y | HIND: down 99.9% S&P 500: up 68.8% −89.5% vs +19.1% a year | HIND trailed the S&P 500 by 168.7 percentage points Trailed |
| 5Y | HIND: down 100.0% S&P 500: up 56.9% −92.7% vs +9.4% a year | HIND trailed the S&P 500 by 156.9 percentage points Trailed |
| 10Y | HIND: down 100.0% S&P 500: up 252.6% −81.0% vs +13.4% a year | HIND trailed the S&P 500 by 352.6 percentage points Trailed |
$10,000 invested in HIND 10 years ago (Nov 4, 2016) would be worth about $0 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$43,500,000.03
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Oct 6, 2016.
Stock splits
5
Latest: 1-for-4 on . Share counts adjust after each split.
All 5 splits
- 1-for-4
- 1-for-25
- 1-for-58
- 1-for-50
- 1-for-10
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
See the note under the price. Over the past five years HIND’s P/E ranged from 0.0× to 1.0×, with a median of 0.4×. How to read P/E
Other valuation measures
- Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - 4.73%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $3.22MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own HIND DCF in Excel. Value ReShape Lifesciences with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- −$1.98Mup 64.8%
- Net income
- −$10.75M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $84.53K | −$547.77K | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | −$5.94M | $3.92M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $198.58K | −$293.97K | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $49.95K | −$308.76K | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $34.63K | −$8.43M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | −$2.07M | −$672.20K | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $31.59K | −$962.91K | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $26.96K | −$685.56K | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $13.60M | −$63.15M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $11.24M | −$46.21M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $8.68M | −$11.39M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $256.94K | −$1.45M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $319.71K | −$10.26M | Paused See the note under the price. |
Margins
- Gross 52.3%
- Operating 378.3%
- Net 544.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $524.47KLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$524.47KLast 12 months
- Capital spending$0.00Last 12 months
- −26.5%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $2.29MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
0% of free cash flow
Balance sheet
- $7.89MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$17.31KAs of Jun 30, 2026
- Net cash$7.87MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 4.37As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −198.7%Last 12 months
Over the last 12 months, ReShape Lifesciences lost money: its net loss was 198.7% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −130.7%Last 12 months
Over the last 12 months, ReShape Lifesciences’s net loss was 130.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About ReShape Lifesciences Inc
ReShape Lifesciences ® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band ® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon ® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
HIND news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
HIND stock FAQ
What is HIND stock’s price today?
ReShape Lifesciences (HIND) traded at $1.58 at the close on , down $0.05 (3.07%) from the previous close of $1.63. Over the past 52 weeks it has traded between $1.57 and $5.88.
If you invested $1,000 in HIND 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in HIND on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $0 if invested five years ago and $279 if invested one year ago. Past performance doesn’t predict future returns.
What is ReShape Lifesciences’s market cap?
ReShape Lifesciences’s market capitalization is about $11.1 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $1.58 (how market cap works).
Does HIND pay a dividend?
ReShape Lifesciences hasn’t paid a dividend in the last twelve months.
What is HIND’s 52-week high and low?
Over the past 52 weeks HIND has traded as low as $1.57 and as high as $5.88. At $1.58 at the close on , it is 73.1% below that high and 0.6% above the low.
What is HIND’s all-time high?
HIND’s highest closing price was $43,500,000.03 on , adjusted for stock splits. At $1.58 at the close on , it is 100.0% below that record.
Has HIND stock ever split?
Yes, five times: 1-for-10 on ; 1-for-50 on ; 1-for-58 on ; 1-for-25 on ; 1-for-4 on .
How has HIND stock performed?
Including dividends and measured to the close on , HIND has returned −54.1% so far this year and −72.1% over the past year, and −100.0% over five years (−92.7% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is ReShape Lifesciences in?
ReShape Lifesciences is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does HIND trade on?
ReShape Lifesciences trades on the Nasdaq under the ticker symbol HIND. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.